Serotonin-glutamate interactions:A new target for antipsychotic drugs

Neuropsychopharmacology

Volumn 21, Issue 6, 1999, Pages S122-S133

  Aghajanian, George K ^a   Marek, Gerard J ^a  

^a Yale University School of Medicine   (United States)

Author keywords

5 HT2A; Antipsychotics; Excitatory postsynaptic potentials; Glutamatergic; Hallucinogens; Metabotropic; Prefrontal cortex; Receptors; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CALCIUM ION; EGLUMETAD; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

BRAIN CORTEX; DRUG TARGETING; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; NEOCORTEX; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0032785165     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00106-2     Document Type: Article

References (68)

1. Aghajanian GK (1980): Mescaline and LSD facilitate the acti-vation of locus coeruleus neurons by peripheral Stimuli. Brain Res 186:492-498
2. Aghajanian GK, Marek GJ (1997): Serotonin induces excita-tory postsynaptic potentials in apical dendrites of neo-cortical pyramidal cells. Neuropharmacology 36:589-599
3. Aghajanian GK, Marek GJ (1999): Serotonin, via 5-HT2Areceptors, increases EPSCs in layer V pyramidal cells ofprefrontal cortex by an asynchronous mode ofglutamate release. Brain Res 825:1-2, 161-171
4. Altar CA, Wasley AM, Neale RF, Stone GA (1986): Typical and atypical antipsychotic occupancy of D2 and S2receptors: An autoradiographic analysis in rat brain.Brain Res Bull 16:517-525
5. Andreasen HC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G, O’Leary DS (1992): Hypofrontal-ity in neuroleptic-naive patients and in patients withchronic schizophrenia: Assessment with xenon-133 single-photon emission computed tomography and theTower of London. Arch Gen Psychiat 49:943-958
6. Andreasen NC, O’Leary DS, Flaun M, Nopoulos P, Watkins GL, Boles Ponto LL (1997): Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neurolep-tic-naive patients. Lancet 349:1730-1734
7. Araneda R, Andrade R (1991): 5-Hydroxytryptamine2and 5-Hydroxytryptamine1Areceptors mediate opposingresponses on membrane excitability in rat associationcortex. Neuroscience 40:399-412
8. Bartrup J, Newberry NR (1994): 5-HT2Areceptor-mediated outward current in C6 glioma cells is mimicked byintracellular IP3release. NeuroReport 5:1245-1248
9. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis withfocal activation of the prefrontal cortex in healthy vol-unteers. Am J Psychiat 154:805-811
10. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, JerabekPA, Trenary M, Tafalla R, Reynolds C, Bunney WE(1992): Frontostriatal disorder of cerebral metabolism innever-medicated schizophrenics. Arch Gen Psychiat49:935-942
11. Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM, Janssen PAJ (1985): Effect of serotoninantagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 85:329-32
12. Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, Szechtman B (1989): Increasedfrontal and reduced parietal glucose metabolism inacute untreated schizophrenia. Psychiat Res 28:119-133
13. Colpaert FC, Janssen PAJ (1983): A characterization of LSD-antagonist effects of pirenperone in the rat. Neurophar-macology 22:1001-1005
14. Conn PJ, Sanders-Bush E (1986): Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT2 binding site. J Neuroscience 6:3669-3675
15. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998): Differential effects of clozapine and haloperidol on ket-amine-induced metabolic activation. Brain Res 812:65-75
16. Ebmeier KP, Blackwood HR, Murray C, Souza V, Walker M, Dougall N, Moffoot APR, O’Carroll RE, Goodwin GM(1993): Single-photon emission computed tomographywith99mTc-exametazime in unmedicated schizophrenicpatients. BiolPsychiat 33:487-495
17. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sed-vall G (1992): Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy inpatients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch GenPsychiat 49:538-544
18. Garratt JC, Alreja M, Aghajanian GK (1993): LSD has high efficacy relative to serotonin in enhancing the cationiccurrent Ih: intracellular studies in rat facial motoneurons. Synapse 13:123-134
19. Geppert M, Goda Y, Hammer RE, Li C, Rosahl TW, Stevens CF, Sudhof TC (1994): Synaptotagmin I: A major Ca2+sensor for transmitter release at a central synapse. Cell79:717-727
20. Glennon RA (1990): Do classical hallucinogens act as 5-HT2agonists or antagonists? Neuropsychopharmacology3:509-517
21. Glennon RA, Titeler M, McKenney JD (1984): Evidence for 5-HT2involvement in the mechanism of action of hallu-cinogenic agents. Life Sci 35:2502-2511
22. Goda Y, Stevens CF (1994): Two components of transmitter release at a central synapse. Proc Nat AcadSci USA91:12942-12946
23. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar K-A, Hermle L, Bull U, Sass H (1999): Neurometabolic effects of psilocybin, 3, 4-methylenedioxyethylamphetamine (MDE) and d-meth-amphetamine in healthy volunteers. Neuropsychophar-macology 20:565-581
24. Hamada S, Senzaki K, Hamaguchi-Hamada K, Tabuchi K, Yamamoto H, Yamamoto T, Yoshikawa S, Okano H, Okado N (1998): Localization of 5-HT2A receptor in ratcerebral cortex and olfactory system revealed by immu-nohistochemistry using two antibodies raised in rabbitand chicken. Mol Brain Res 54:199-211
25. Haznedar MM, Buchsbaum MS, Luu C, Hazlett EA, Siegel BV, Lohr J, Wu J, Haier RJ, Bunney WEJ (1997):Decreased anterior cingulate gyrus metabolic rate inschizophrenia. Am J Psychiat 154:682-684
26. Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992): Mesca-line-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. BiolPsychiat 32:976-991
27. Herrero I, Castro E, Miras-Portugal MT, Sanchez-Prieto J (1996): Two components of glutamate exocytosis differ-entially affected by presynaptic modulation. J Neuro-chem 67:2346-2354
28. Jakab RL, Goldman-Rakic PS (1998): 5-Hydroxytryptamine2Aserotonin receptors in the primate cerebral cortex: Pos-sible site of action of hallucinogenic and antipsychoticdrugs in pyramidal cell apical dendrites. Proc Nat AcadSci USA 95:735-740
29. Kapur S, Zipursky RB, Remington G (1999): Clinical and the-oretical implications of 5-HT2and D2receptor occu-pancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiat 156:286-293
30. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995): Ketamine activates psychosis and alters limbic bloodflow in schizophrenia. NeuroReport 6:869-872
31. Leysen JE, Niemegeers CJE, Tollemaere JP, Lauduron PM (1978): Serotonergic component of neuroleptic recep-tors. Nature 272:168-171
32. 2+binding properties of synaptotagmins. JBiolChem 270:24898-24902
33. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998): Serotonergic basis of anti-psychotic drug effects in schizophrenia. BiolPsychiat44:1099-1117
34. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT (1997): Selective visualization of rat brain 5-HT2Arecep-tors by autoradiography with [3H]MDL 100, 907. Nau-nyn-Schmiedeberg’s Arch Pharmacol 356:446-454
35. Marek GJ, Aghajanian GK (1996): LSD and the phenethy-lamine hallucinogen DOI are potent partial agonists at 5-HT2Areceptors on neurons in the rat piriform cortex.J PharmacolExpTher 278:1373-1382
36. Marek GJ, Aghajanian GK (1998): 5-HT-induced EPSCs in neocortical layer V pyramidal cell of prefrontal cortex:Suppression by m opiate receptor activation. Neuro-science 86:485-497
37. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (1999): Physiological antagonism between 5-hydroxy-tryptamine2Aand group II metabotropic glutamatereceptors in prefrontal cortex. J PharmacolExpTher, inpress.
38. Marek GJ, Aghajanian GK (1999): 5-HT2Areceptor or a2-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial pre-frontal cortex. Eur J Pharmacol 367:197-206
39. McCall RB, Aghajanian GK (1980): Hallucinogens potentiate responses to serotonin and norepinephrine in the facialmotor nucleus. Life Sci 26:1149-1156
40. Meltzer HY, Matsubara S, Lee JC (1989): Classification of typical and atypical antipsychotic drugs on the basis ofdopamine D-1, D-2, and serotonin-2 pKi values. J PharmacolExpTher 251:238-246
41. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
42. Mengod G, Pompeiano M, Martinez-Mir MI, Palacios JM (1990): Localization of the mRNA for the 5-HT2receptorby in situ hybridization histochemistry: Correlationwith the distribution of receptor binding sites. Brain Res524:139-143
43. Mochida S, Sheng S-H, Baker C, Kobaysashi H, Catterall WA (1996): Inhibition of neurotransmission by peptides con-taining the synaptic protein interaction site of N-typeCa2+channels. Neuron 17:781-788
44. Moghaddam B, Adams B (1998): Stimulation of group II metabotropic glutamate receptors normalizes the cogni-tive and motoric effects of phencylidine. Science281:1349-1352
45. Moghaddam B, Adams B, Verma A, Daly D (1997): Activa-tion of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with prefrontal cortex. J Neurosci 17:2921-2927
46. Ohishi H, Neki A, Mizuno N (1998): Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: An immuno-histochemical study with a monoclonal antibody.Neurosci Res 30:65-82
47. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993): Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009-1018
48. Parellada E, Catafau AM, Bernardo M, Lomena F, Gonzalez-Monclus E, Setoain J (1994): Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients:A resting and activation SPECT study. Psychiat ResNeuroimaging 55:131-139
49. Pazos A, Palacios JM (1985): Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Sero-tonin-1 receptors. Brain Res 346:205-230
50. Peroutka SJ, Snyder SH (1979): Multiple serotonin receptors: differential binding of3H-serotonin, 3H-lysergic aciddiethylamide and3H-spiroperidol. MolPharmacol16:687-699
51. Peroutka SJ, Snyder SH (1980): Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. Am J Psy-chiat 137:1518-1522
52. Rasmussen K, Aghajanian GK (1986): Effects of hallucino-gens on spontaneous and sensory-evoked locus coer-uleus unit activity in the rat: Reversal by selective 5-HT2antagonists. Brain Res 385:395-400
53. Sanders-Bush E, Burris KD, Knoth K (1988): Lysergic acid diethylamide and 2, 5-dimethoxy-4-methylampheta-mine are partial agonists at serotonin receptors linkedto phosphoinositide hydrolysis. J PharmacolExpTher246:924-928
54. Schiller J, Schiller Y, Stuart G, Sakmann B (1997): Calcium action potentials restricted to distal apical dendrites ofrat neocortical pyramidal neurons. J PhysiolLond505:605-616
55. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL, Burnett JP, Belegaje R, Bleak-man D, Monn JA (1997): LY354740 is a potent andhighly selective group II metabotropic glutamate recep-tor agonist in cells expressing human glutamate recep-tors. Neuropharmacology 36:1-11
56. Sheldon PW, Aghajanian GK (1990): Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriformcortex: Evidence for the involvement of a 5-HT2-acti-vated interneuron. Brain Res 506:62-69
57. Stanley EF (1997): The calcium channel and the organization of the presynaptic transmitter release face. TINS 20:404-409
58. Tamminga CA (1998): Sertotonin and schizophrenia. BiolPsychiat 44:1079-1080
59. Tanaka E, North RA (1993): Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophys69:1749-1757
60. 2+and glutamaterelease. J Neurochem 53:1693-1699
61. Titeler M, Lyon RA, Glennon RA (1988): Radioligand bind-ing evidence implicates the brain 5-HT2receptor as a site of action for LSD and phenylisopropylaminehallu-cinogens. Psychopharmacology 94:213-216
62. Tobi D, Wiser O, Trus M, Atlas D (1998): N-type voltage-sensitive calcium interacts with syntaxin, synaptobrevin and SNAP-25 in a multiprotein complex. ReceptorsChannels 6:89-98
63. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997a): Metabolichyperfrontality and psychopathology in the ketaminemodel of psychosis using positron emission tomogra-phy (PET) and [18F]fluorodeoxyglucose (FDG). EurNeuropsychopharmacology 7:9-24
64. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997b): Positron emission tomography and fluorodeoxyglucose studies of meta-bolichyperfrontality and psychopathology in the psilo-cybin model of psychosis. Neuropsychopharmacology16:357-372
65. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998): Psilocybin inducesschizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897-3902
66. Weinberger DR, Berman KF, Zec RF (1986): Physiological dysfunction of dorsolateral prefrontal cortex in schizo-phrenia: I. Regional cerebral blood flow (rCBF) evi-dence. Arch Gen Psychiat 43:114-125
67. Willins DL, Deutch AY, Roth BL (1997): Serotonin 5-HT2Areceptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82
68. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L (1995): Comparative localization of serotonin1A, 1C, and2receptor subtype mRNAs in rat brain. J Comp Neurol351:357-373